Targeting c-Myc as a novel approach for hepatocellular carcinoma.
Explore this paper's citation graph
Summary
The possibility of treating HCC by inhibiting c-Myc and the pros and cons of such an approach are explored, as well as the association of c- myc activation in chronic hepatitis B infection and the upregulation of HIF-1/VEGF.
- Type
- article
- Published
- 2010-01-27
- Cited by
- 139
- References
- 55
- Access
- Open access
- OpenAlex
- https://openalex.org/W203927818
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:41817542
Keywords
Hepatocellular carcinoma, Medicine, Downregulation and upregulation, Cancer research, Carcinogenesis
References
- Direct activation of TERT transcription by c-MYC
- Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells
- Chimaeras of Myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells
- Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer.
- A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice.
- Myc represses transcription through recruitment of DNA methyltransferase corepressor
- Amplification of c-myc in Hepatocellular Carcinoma: Correlation with Clinicopathologic Features, Proliferative Activity and p53 Overexpression
- In silico identification of transcriptional regulators associated with c-Myc.
- High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma.
- Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein.
- Sin3 corepressor function in Myc-induced transcription and transformation.
- Role of the murine reprogramming factors in the induction of pluripotency
- Etiology‐dependent molecular mechanisms in human hepatocarcinogenesis
- The mouse C/EBPδ gene promoter is regulated by STAT3 and Sp1 transcriptional activators, chromatin remodeling and c‐Myc repression
- Role of hypoxia-inducible factor-alpha in hepatitis-B-virus X protein-mediated MDR1 activation.
- Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells
- MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
- Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter
- A genetic screen to identify genes that rescue the slow growth phenotype of c-myc null fibroblasts
- The c-Myc target gene network.
Cited by
- Chemical inhibition reveals differential requirements of signaling pathways in krasV12- and Myc-induced liver tumors in transgenic zebrafish
- The WNT signalling pathway in Ewing sarcoma/primitive neuroectodermal tumour : an immunohistochemical investigation
- SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation
- Wpływ ftalanu dibutylu (DBP) na poziom metylacji i ekspresji genu p53 w wątrobie szczurów Wistar
- Mechanism studies on anti-HepG2 cell proliferation of phenanthroline derivatives as G-quadruplex DNA stabilizers.
- Steroid Receptor Coactivator 1 Promotes Human Hepatocellular Carcinoma Progression by Enhancing Wnt/β-Catenin Signaling*
- Targeting hypoxia-inducible factor-2α enhances sorafenib antitumor activity via β-catenin/C-Myc-dependent pathways in hepatocellular carcinoma.
- Aurora kinase A mediates c‐Myc's oncogenic effects in hepatocellular carcinoma
- MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma
- CDCA7L promotes hepatocellular carcinoma progression by regulating the cell cycle.
- Effect of Celergen, a marine derivative, on in vitro hepatocarcinogenesis.
- Targeting apoptosis pathways in cancer stem cells.
- In-silico drug screening and potential target identification for hepatocellular carcinoma using Support Vector Machines based on drug screening result.
- Inhibition of Hec1 as a novel approach for treatment of primary liver cancer
- The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations
- Immortalization and malignant transformation of Eukaryotic cells
- Carbon Nanotubes: An Emerging Drug Carrier for Targeting Cancer Cells
- Changes of c-Myc and DNMT1 mRNA and protein levels in the rat livers induced by dibutyl phthalate treatment
- Medulloblastoma molecular dissection: the way toward targeted therapy
- Ursolic acid from Oldenlandia diffusa induces apoptosis via activation of caspases and phosphorylation of glycogen synthase kinase 3 beta in SK-OV-3 ovarian cancer cells.
Related papers
- Enzyme-Instructed Assembly and Disassembly Processes for Targeting Downregulation in Cancer Cells
- Downregulation of p21/WAF1 expression by thymidylate synthase.
- Downregulation of POLD4 in Calu6 cells results in G1-S blockage through suppression of the Akt-Skp2-p27 pathway.
- Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey.
- Upregulation of β3-adrenoceptors—a general marker of and protective mechanism against hypoxia?
- Maritoclax Enhances TRAIL-Induced Apoptosis via CHOP-Mediated Upregulation of DR5 and miR-708-Mediated Downregulation of cFLIP
- Relative contribution of molecular mechanisms to cumulative ligand-mediated downregulation of GRα.
- Downregulation of RBM17 enhances cisplatin sensitivity and inhibits cell invasion in human hypopharyngeal cancer cells
- HCC-Mark: a simple non-invasive model based on routine parameters for predicting hepatitis C virus related hepatocellular carcinoma
- Diethylnitrosamine-induced liver tumorigenesis in mice.